Biologics Market

Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030Biologics is a product that is produced from living organisms or contain components of living organisms. Biologics are medicines that are developed from blood, proteins, viruses, or living organisms, and are used to prevent, treat, and cure many health conditions. Biologicals are a diverse group of medicines which includes vaccines, growth factors, immune modulators, monoclonal antibodies, as well as products derived from human blood and plasma. The main types of biologics are monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are created in a laboratory to combat a specific infection. Biologic drugs are the most advanced therapies available for the treatment of a wide range of diseases and conditions. Certain biologic medications are used to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases. Biologics have transformed cancer treatment, delayed or reversed the progression of immune-related conditions, transformed the lives of people with rare diseases, and given hope to many patients who previously had no effective treatment options for their condition.

Market Dynamics

Increasing burden of infectious, autoimmune, and chronic diseases, and rising demand for biologics, higher acceptability for innovative therapies, increasing number of clinical trials and research and development activities are the major factors that are expected to drive growth of the global biologics market during the forecast period. Moreover, in March 2022, TG Therapeutics Inc., Biopharmaceutical Company hasannounced that U.S. FDA extended the prescription drug user fee act (PDUFA) for Instance June 25, 2022, for the Biologics License Application for ublituximab for treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Key features of the study:This report provides in-depth analysis of the global biologics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base yearIt elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this marketThis study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key playersIt profiles key players in the global biologics market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategiesKey companies covered as a part of this study include Novartis AG, AstraZeneca PLC, Bayer AG., Sanofi SA, Pfizer Inc, Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC, Amgen Inc AbbVie Inc, F. Hoffmann-La Roche AG, Eli Lilly and Company, and AGC Biologics.Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tacticsGlobal Biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analystsStakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics marketDetailed Segmentation:Global Biologics market, By Product:Monoclonal Antibodies

Vaccines

Recombinant Hormones/Proteins

Cellular-based Biologics

Gene-based Biologics

OthersGlobal Biologics market, By Application:Cancer

Infectious Diseases

Autoimmune Diseases

OthersGlobal Biologics Market, By Region:North America By Country:U.S.

Canada

Latin America By Country:Brazil

Mexico

Argentina

Rest of Latin America

Europe By Country:Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific By Country:China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East By Country:GCC Countries

Israel

Rest of Middle East

Africa By Country/Region:South Africa

Central Africa

North AfricaCompany ProfilesNovartis AG Company Highlights Products Portfolio Key Highlights Financial Performance StrategiesAstraZeneca PLC

Bayer AG

Sanofi SA

Pfizer Inc

Merck & Co

Johnson and Johnson

GlaxoSmithKline PLC

Amgen Inc

AbbVie Inc

F. Hoffmann-La Roche AG

Eli Lilly and Company

AGC Biologics

“*” marked represents similar segmentation in other categories in the respective section.